Noncore operations sold by listed Japanese firms soar over ¥5 trillion
The number of businesses and operations sold by listed companies in January-September stood at 294, with the values of the deals totaling ¥5.1645 trillion.
Japan in vaccine talks with Moderna to cover 20 million people
If they reach a deal, it will be a major step toward the government's goal of securing enough medicine to inoculate everyone in the first half of 2021.
Takeda Pharmaceutical Co. agreed to sell its Japanese consumer health care business for ¥242 billion ($2.3 billion) to Blackstone Group Inc., which plans to take the over-the-counter medication unit public in about five years. For the drugmaker, the sale could represent one of the last ...
Takeda on track to sell OTC drug unit to Blackstone for ¥300 billion
Takeda is aiming to reduce debts after its purchase of Irish drugmaker Shire in January last year, the largest-ever Japanese acquisition of a foreign company.
Taisho emerges as lead bidder for Takeda $3 billion consumer unit
Taisho Pharmaceutical Holdings Co. has emerged as the leading contender to acquire Takeda Pharmaceutical Co.’s Japanese consumer health care business, according to people familiar with the matter. The company is in advanced talks with Takeda on terms of a transaction, and the two parties aim ...
Takeda considers sale of OTC drug unit to focus on profitable products
Takeda Pharmaceutical Co. is considering selling its over-the-counter medicine unit for around ¥400 billion ($3.7 billion) to focus on developing cancer treatments and other advanced medical-use drugs that can generate higher profitability, a source said Monday. The envisioned sale of Takeda Consumer Healthcare Co. comes ...
Takeda says trial based on blood of recovered virus patients could start in July
Fighting disease with blood from survivors is an ancient strategy that has not been well tested for the novel coronavirus.
Japan's largest drugmaker working to develop virus treatment, Dow Jones reports
Takeda Pharmaceutical Co. is developing an experimental therapy for the novel coronavirus with the goal of making it available in 9 to 18 months, the nation's largest drugmaker said. "We will do all that we can to address the novel coronavirus threat," Dr. Rajeev Venkayya, ...
As COVID-19 spreads, Takeda CEO urges more industry investment in vaccines
The spread of novel coronavirus infections is starting to make one thing clear: More vaccine investment is needed, the CEO of Asia's biggest drugmaker said. "The world has to be more proactive than reactive," Christophe Weber, CEO of Takeda Pharmaceutical Co., said in an interview. Although ...
Takeda's dengue vaccine said effective overall in study but with major limitation
Takeda Pharmaceutical Co.'s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue. Takeda's vaccine was 80.2 percent effective at ...
Takeda nears deal on sale of Russia, Mideast and Africa assets to private equity firms
Takeda Pharmaceutical Co. is nearing the sale of a portfolio of assets in the Middle East, Africa and Russia to separate buyout firms that could help the drugmaker raise about $1 billion to reduce debt, according to people familiar with the matter. The company is ...
Takeda Pharmaceutical to sell drug assets in emerging markets and Europe, sources say
Takeda Pharmaceutical Co. is close to selling some assets in emerging markets and Western Europe, people familiar with the matter said, in a move that would help the Japanese drugmaker reduce its debt pile. Takeda may announce the sale of over-the-counter and prescription drugs in ...
